Neuromyelitis Optica Spectrum Disorder Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The Global Neuromyelitis Optica Spectrum Disorder Market is segmented by Treatment (Monoclonal Antibody Drugs, Immunosuppressive Agents, Plasma Exchange Therapy, and Others), and Geography (North America, Europe, Asia-Pacific, Rest of World). The report offers the value (in USD million) for the above segments.

Market Snapshot

neuromyelitis optica spectrum disorder market size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 6 %
 neuromyelitis optica spectrum disorder market share

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Neuromyelitis Optica Spectrum Disorder market is projected to grow with a CAGR of 6% during the forecast period (2022 - 2027).

The COVID-19 pandemic has been continuing to transform the growth of various markets, and the immediate impact of the outbreak is varied. While a few healthcare industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. Initially, the global COVID-19 outbreak and the lockdown scenario in various countries have imposed some challenges on the market, as hospitals and clinics were forced to suspend services to prevent the spread of the SARS-CoV-2 virus. According to an article published by the National Center for Biotechnology Information, in 2021, titled "The impact of COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany", during the different pandemic periods in 2020, there was a significant drop in multiple sclerosis and neuromyelitis optica spectrum disorder patient hospitalizations, with the greatest significant reduction occurring during the pandemic's initial wave. The delayed or interrupted treatment due to the pandemic is thus increasing the risk of relapse in patients. With resumed services and procedures, the hospital visits have increased due to which the demand for treatment will increase, over the forecast period.

The factors propelling the growth of the market are the increasing incidence and prevalence of neuromyelitis optica spectrum disorder (NMOSD), increasing research and development activities, product approvals, and rising demand for better treatment options for neuromyelitis optica spectrum disorder patients. For instance, according to an article published by Neurology, in 2021, titled "Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review", the findings revealed that the incidence and prevalence rate of neuromyelitis optica spectrum disorder was highest in the Afro-Caribbean area and lowest in Australia and New Zealand areas.

Furthermore, the increasing research and development activities and product approvals by the companies are also contributing to the growth of the market. For instance, in August 2020, Chugai Pharmaceuticals launched Enspryng Subcutaneous Injection for the prevention of relapses of neuromyelitis optica spectrum disorder (NMOSD) including neuromyelitis Optica (NMO). Similarly, In June 2020, The United States Food and Drug Administration (FDA) approved Viela Bio’s UPLINZA, for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD).

However, the high cost of therapy for neuromyelitis optica is projected to stifle market expansion.

Scope of the Report

As per the scope of the report, Neuromyelitis Optica Spectrum Disorder is an autoimmune disorder in which white blood cells and antibodies attack and damage the optic nerve, resulting in discomfort and visual loss, spinal cord causing paralysis, loss of sensation in the legs and arms, and problems with bladder and bowel function. The Global Neuromyelitis Optica Spectrum Disorder Market is segmented by Treatment (Immunosuppressive Agents, Plasma Exchange Therapy, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (in USD million) for the above segments.

By Treatment
Monoclonal Antibody Drugs
Immunosuppressive Agents
Plasma Exchange Therapy
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World

Report scope can be customized per your requirements. Click here.

Key Market Trends

Monoclonal Antibody Drugs Segment Expects to Register a High CAGR in the Forecast Period

The monoclonal antibody drugs segment is expected to hold the largest share in this market segment. It is considered an emerging therapy as well as a better option for autoimmune diseases including neuromyelitis optica spectrum disorder due to its high efficacy and tolerability. B cells play a pathogenic role by producing auto-antibodies, secretion of cytokines/chemokines, and antigen presentation-T cell interactions in neuromyelitis optica spectrum disorder. As a result, monoclonal antibody-mediated B cell depletion has become a treatment option for neuromyelitis optica spectrum disorder (NMOSD). Some of the monoclonal antibody drugs used for the treatment of NMOSD include Rituximab, Inebilizumab, Tocilizumab, Satralizumab, and Eculizumab.

The increasing monoclonal anti-body drug approvals and rising research and development activities by the players for developing effective treatment options for patients with neuromyelitis optica spectrum disorder are also increasing the market growth. For instance, in November 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), granted a market authorization to Horizon's UPLINZA, as a monotherapy, for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who tested positive for anti-aquaporin-4 immunoglobulin G ( (AQP4-IgG+) antibodies.

Thus, the increasing efficacy and tolerability of monoclonal antibody drugs, rising product approvals, and research and development activities by the market players are propelling the growth of the segment which further increases the market growth over the forecast period.

neuromyelitis optica spectrum disorder market forecast

North America is Expected to Have the Significant Market Share

North America is witnessed to have a large market share owing to the factors such as the increasing incidence and prevalence of neuromyelitis optica spectrum disorder, well-established healthcare infrastructure, and the availability of efficient treatment methods.

The increasing incidences of neuromyelitis optica spectrum disorder is the key factor driving the growth of the market over the forecast period. According to an article published by the National Center for Biotechnology Information, in 2021, titled "Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database", neuromyelitis optica spectrum disorder affects about 15,000 people in the United States.

In addition, the increasing company's research and development activities and non-profit organizations' financial assistance programs for people with neuromyelitis optica spectrum disorder are also contributing to the growth of the market in the region. For instance, in November 2021, The Patient Access Network (PAN) Foundation opened a new financial assistance program for people living with neuromyelitis optica spectrum disorder.

Furthermore, the increasing product approvals in the region are also contributing to the growth of the market over the forecast period. For instance, in August 2020, the United States Food and Drug Administration (FDA) approved Genetech's Enspryng (satralizumab-mwge), for the treatment of adult patients, with neuromyelitis optica spectrum disorder (NMOSD), who are anti-aquaporin-4 or AQP4 antibody-positive.

Thus, the increasing prevalence of neuromyelitis optica spectrum disorder, rising research and development activities as well as increasing product approvals are likely to increase the market growth in the near future.

neuromyelitis optica spectrum disorder market growth

Competitive Landscape

The neuromyelitis optica spectrum disorder market is moderatively competitive with the presence of a large number of players in the market. The companies are focusing on adopting various business strategies such as collaboration, acquisitions, and product approval to withhold the market position. Some of the key players are Hoffmann-La Roche Ltd, Horizon Therapeutics plc, TG Therapeutics, Opexa Therapeutics, and Mitsubishi Tanabe Pharma.

Recent Development

In May 2022, The European Commission approved Horizon Therapeutics's drug, UPLIZNA, as monotherapy, for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD).

In December 2021, Merck KGaA acquired Chord therapeutics, a clinical stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases. This acquisition will enable the company to expand its neurology pipeline to develop Chord's lead drug candidate, CRD1 (cladribine), for the treatment of Myasthenia gravisand neuromyelitis optica spectrum disorder.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Neuromyelitis Optica Spectrum Disorder

      2. 4.2.2 Increasing Research and Development Activities, Product Approvals and Rising Demand for Better Treatment Options

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Therapy for Neuromyelitis Optica Spectrum Disorder

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment

      1. 5.1.1 Monoclonal Antibody Drugs

      2. 5.1.2 Immunosuppressive Agents

      3. 5.1.3 Plasma Exchange Therapy

      4. 5.1.4 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Rest of the World

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Hoffmann-La Roche Ltd

      2. 6.1.2 Horizon Therapeutics plc (Viela Bio)

      3. 6.1.3 AstraZeneca

      4. 6.1.4 Mitsubishi Tanabe Pharma

      5. 6.1.5 Harbour BioMed

      6. 6.1.6 RemeGen

      7. 6.1.7 Teva Pharmaceutical Industries Ltd

      8. 6.1.8 Horizon Therapeutics plc

      9. 6.1.9 TG Therapeutics

      10. 6.1.10 Opexa Therapeutics

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Neuromyelitis Optica Spectrum Disorder Market market is studied from 2019 - 2027.

The Global Neuromyelitis Optica Spectrum Disorder Market is growing at a CAGR of 6% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Hoffmann-La Roche Ltd, TG Therapeutics, Opexa Therapeutics, Mitsubishi Tanabe Pharma, Horizon Therapeutics plc (Viela Bio) are the major companies operating in Global Neuromyelitis Optica Spectrum Disorder Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!